Archive | October, 2018
PM 2 site 207

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.

J Autism Dev Disord. 2018 Oct 31. doi: 10.1007/s10803-018-3808-2. [Epub ahead of print] Aran A1, Cassuto H2, Lubotzky A3, Wattad N3, Hazan E3. Author information Abstract Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in […]

Aging thumb site

THC for age-related cognitive decline?

Editorial Advance Articles Yosef Sarne 1 1 Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel received: October 31, 2018 ; published: November 12, 2018 How to Cite Copyright: Sarne. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), […]

PM 2 site 207

Dermatology-Related Uses of Medical Cannabis Promoted by Dispensaries in Canada, Europe, and the United States.

J Cutan Med Surg. 2018 Oct 31:1203475418808761. doi: 10.1177/1203475418808761. [Epub ahead of print] Lim M1, Kirchhof MG1. Author information Abstract There is a growing interest in the use of medical cannabis for a variety of dermatologic conditions. Despite the lack of evidence to validate the effectiveness and safety of marijuana, it is approved to treat […]

PM 2 site 207


Format: Abstract Source Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Excerpt Chocolate contains small amounts of caffeine and larger amounts of the closely related compound, theobromine. It also contains anandamide and two related compounds that stimulate cannabinoid receptors, tryptophan, and polyphenols.[1][2] All of these compounds are detectable in […]

PM 2 site 207

Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study.

Clin Exp Rheumatol. 2018 Oct 30. [Epub ahead of print] Yassin M1, Oron A2, Robinson D3. Author information Abstract OBJECTIVES: Low back pain (LBP) occurs in many patients with fibromyalgia (FM). The current study aimed to assess the possible pain and function amelioration associated with medical cannabis therapy (MCT) in this setting. METHODS: 31 patients […]

PM 2 site 207

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.

CNS Drugs. 2018 Oct 30. doi: 10.1007/s40263-018-0578-5. [Epub ahead of print] Taylor L1, Gidal B2, Blakey G3, Tayo B1, Morrison G4. Author information Abstract BACKGROUND: A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and […]

PM 2 site 207

Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model.

J Surg Res. 2019 Mar;235:210-215. doi: 10.1016/j.jss.2018.08.055. Epub 2018 Oct 30. Simmerman E1, Qin X2, Yu JC3, Baban B4. Author information Abstract BACKGROUND: Malignant melanoma is a complex malignancy with significant morbidity and mortality. The incidence continues to rise, and despite advances in treatment, the prognosis is poor. Thus, it is necessary to develop novel […]

PM 2 site 207

Medical Use of Cannabinoids.

Drugs. 2018 Oct 29. doi: 10.1007/s40265-018-0996-1. [Epub ahead of print] Fraguas-Sánchez AI1, Torres-Suárez AI2,3. Author information Abstract Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. In recent decades, the endocannabinoid system has attracted considerable interest as a potential therapeutic target in numerous pathological conditions. Its involvement in […]

PM 2 site 207

The Endocannabinoid System and Oligodendrocytes in Health and Disease.

Front Neurosci. 2018 Oct 26;12:733. doi: 10.3389/fnins.2018.00733. eCollection 2018. Ilyasov AA1,2, Milligan CE1,3, Pharr EP1,4, Howlett AC1,2. Author information Abstract Cannabinoid-based interventions are being explored for central nervous system (CNS) pathologies such as neurodegeneration, demyelination, epilepsy, stroke, and trauma. As these disease states involve dysregulation of myelin integrity and/or remyelination, it is important to consider […]

PM 2 site 207

The pharmacological management of Lennox-Gastaut syndrome and critical literature review.

Seizure. 2018 Oct 26;63:17-25. doi: 10.1016/j.seizure.2018.10.016. [Epub ahead of print] Verrotti A1, Striano P2, Iapadre G3, Zagaroli L4, Bonanni P5, Coppola G6, Elia M7, Mecarelli O8, Franzoni E9, Liso P10, Vigevano F11, Curatolo P12. Author information Abstract Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy with a prevalence of 1-2% of all patients with epilepsy. […]